The objective of this study is to determine whether pharmacokinetic parameters of anidulafungin correlate with disease severity and plasma protein levels in critically ill patients.

One of the risk factors for mortality of patients with candidemia is inadequate antifungal therapy. The first days in the intensive care unit (ICU), patients are unstable and it can be questioned whether therapeutic levels of anidulafungin are reached after a standard loading scheme. At this moment there are several clues that the PK of anidulafungin in critically ill patients is different, but an overall picture is lacking.

For the investigation of the correlation of the pharmacokinetics of anidulafungin and the disease severity a full pharmacokinetic profile will be obtained. Predictive scoring systems will be used to assess disease severity.

Inclusion Criteria:

• treatment with anidulafungin
• at least 18 years of age
• invasive candidiasis
• admitted to an intensive care unit

Exclusion Criteria:

• allergic to anidulafungin or its excipients
• contra-indication stated in SPC
• neutropenia

Adult patients with invasive candidiasis admitted to an intensive care unit.